Cosmos Health to Acquire 59,000-Sq-Ft GMP Plant with $24M Asset Base
COSM•Cosmos Health signed a LOI to acquire Doc Pharma, a GMP-licensed European manufacturer with a 59,000-sq-ft facility, $24 million in assets, $6.7 million annual revenue and $3.2 million gross profit. The deal should boost vertical integration, economies of scale, margin expansion and the branded generics and OTC portfolio.
1. Acquisition Overview
Cosmos Health has entered a non-binding LOI to acquire 100% of Doc Pharma S.A., a fully licensed GMP European manufacturer. The transaction aims to integrate end-to-end production capabilities by bringing a state-of-the-art facility in-house.
2. Facility and Financial Profile
Doc Pharma operates a 59,000-square-foot GMP-licensed plant certified to ISO, Kosher and Halal standards, with registrations in the UAE, Qatar, Iraq and Lebanon. The business holds a $24 million asset base and delivered $6.7 million in revenue and $3.2 million in gross profit annually.
3. Strategic Benefits and Next Steps
The acquisition is expected to deepen vertical integration, unlock economies of scale, improve margins and broaden Cosmos Health’s branded generics and OTC offerings. As a related-party transaction, it will undergo independent fairness review, PCAOB audit and requires shareholder approval.
